๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Benxi
Clinical trial register · China

Clinical Trials in Benxi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Benxi

4 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window
NCT07476898Stroke
First Hospital of China Medical University
Phase 3
864
Fuzhou, Anshan, Benxi, Chaoyang, Dalian, Dandong, Fushun, Fuxin
2026-03-01
Recruiting
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
NCT07220538Ischemic Stroke Hospitalized, Impairment, Cognitive
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Beipiao, Benxi, Chenzhou, Chifeng, Dalian
2025-11-28
Recruiting
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
NCT07581210Acute Ischemic Stroke
Shanghai QuietD Biotechnology Co., Ltd.
Phase 2
120
Meizhou, Luoyang, Nanyang, Changchun, Meihekou, Benxi, Fuxin, Shengyang
2025-10-14
Active, closed
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267Hyperkalemia
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-china/city/benxi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4 of those studies with a site in Benxi.

How many clinical trials are recruiting in Benxi?

2 of the 4 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Benxi), 4 studies
PhaseStudiesRecruitingShare
Not applicable1025%
Phase 21125%
Phase 31025%
Phase 41125%

Most active sponsors

Lead sponsors with the most studies (Benxi)
Lead sponsorStudiesRecruiting
AstraZeneca10
Dr. Willmar Schwabe GmbH & Co. KG11
First Hospital of China Medical University10
Shanghai QuietD Biotechnology Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.